The biotech is entering a new era.

President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort ...

Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be.

Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped ...

Moderna (MRNA) closed at $146.69 in the latest trading session, marking a +1.89% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.48%. At the same time, ...

Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 2.9% in the afternoon session after Rothschild & Co Redburn ...

Moderna's upside hinges on Intismeran’s ability to scale across multiple tumor types, not just melanoma. Learn why MRNA stock ...

Moderna and Merck said on Wednesday that a personalized mRNA cancer vaccine reduced the ​risk of recurrence and spread of ...

But what has the stock done for shareholders lately? How has it done over the past five years? Not so great. It has averaged ...

Dow Jones futures: Despite Friday's bounce, the stock market had a tough week amid $100 oil prices and surging Treasury ...

The vaccine maker is making an increasingly robust case that it isn't just a pandemic stock.